Insulin-like growth factor I (IGF-I), a target hormone mediating most of the growth effects of GH, suppresses GH gene expression in a feedback regulatory loop, which may be either endocrine or paracrine in nature. Although IGF-I has been shown to directly attenuate GH gene transcription, the relationship of IGF-I binding and action in the somatotroph cell remains unclear. Therefore, IGF-I binding and action were compared in two different pituitary cell lines both secreting GH. Recombinant human IGF-I attenuated GH secretion in GC cells by up to 70% after 48 h in a dose-dependent manner. Surprisingly, IGF-I failed to suppress GH secretion in GH3 cells, a clonally related pituitary cell line. Binding studies showed that although the KD for IGF-I was similar in both cell types, GC cells contain 3-fold more IGF-I binding sites compared to GH3 cells, possibly explaining their resistance to IGF-I action. Nevertheless, both cell lines possessed abundant and similar binding sites for insulin. These results imply that the IGF-I signal for GH gene regulation is receptor-mediated and directly correlated with the number of pituitary IGF-I binding sites. Availability of pituitary IGF-I binding sites may therefore be important in determining the level of GH expression by the somatotroph.
No takes yet. Share an insight, caveat, or question.
Yamasaki et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: